Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EASIER: Replacing Enfuvirtide with Raltegravir in HIV-1
NCT00454337Phase 3Completed
- Sponsor
- ANRS
- Start
- May 2007
- Primary completion
- Sep 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of raltegravir in human immunodeficiency virus infection (HIV) (2 arms), sponsored by ANRS. Primary endpoint: Proportion of Patients with Virologic Failure at 24 weeks. Started May 2007; status: completed.
02
Drugs
raltegravir
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT00454337.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00454337.